a new vision for precision medicine
Advancing Precision Medicine in
Cancer and Inflammatory Disease
Mission & Vision
Seeing the Unseen
Observation. Insights. Action.
We are pioneering new precision medicines in inflammatory disease and cancer by harnessing the power of single-cell RNA sequencing and human biology at scale.
Single-Cell Genomics & Machine Learning
Celsius is a
New Way of Seeing
By harnessing the power of single-cell genomics and machine learning, we have a high-resolution view into cellular programs associated with cancer and inflammatory disease.
Deeper Understanding of Complex Disease
New Insights Enable New Precision Medicines
With a deeper, clearer understanding of cells in patients with complex disease, we can identify novel insights that translate into new targets and patient subsets.
Developing Precision Therapies for Complex Diseases
The promise of precision medicine has yet to benefit immuno-oncology and immuno-inflammatory diseases such as inflammatory bowel disease because they are multifactorial and not driven by a single, druggable genetic lesion. With our SCOPE platform, we now have the ability to “see” cells in a particular therapeutic setting; generate unmatched insights into the disease biology; and enabled by an automated machine learning platform, deliver insights rapidly.
Our first therapeutic candidate is an anti-TREM1 antibody for the treatment of inflammatory bowel disease (IBD). TREM1, a myeloid target with a central role in IBD, was identified through machine learning-enabled analysis of hundreds of clinical samples.
We have multiple ongoing drug discovery programs in oncology directed towards targets identified through analysis of hundreds of solid tumor samples from patients.
Achieving More, Together
At Celsius, we understand that innovating at the frontier of precision medicine in cancer and inflammatory disease requires multiple perspectives. Our work is based on multidisciplinary collaboration where every viewpoint is encouraged and valued.